Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
10.93
-0.01 (-0.09%)
Jun 27, 2025, 4:00 PM - Market closed
Upstream Bio Employees
Upstream Bio had 52 employees as of December 31, 2024.
Employees
52
Change
n/a
Growth
n/a
Revenue / Employee
$44,154
Profits / Employee
-$1,724,135
Market Cap
587.97M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
UPB News
- 13 days ago - Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewsWire
- 23 days ago - Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 - GlobeNewsWire
- 24 days ago - Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Upstream Bio Appoints Stacy Price as Chief Technology Officer - GlobeNewsWire
- 7 weeks ago - Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs - GlobeNewsWire
- 2 months ago - Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent - Seeking Alpha
- 3 months ago - 3 Dividend Giants To Buy As Tariffs Hit Stocks - Benzinga
- 3 months ago - Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire